New FDA-Approved Treatment for RKD

The FDA has approved Gazyva® (obinutuzumab) for adults and children ages 2 and older with idiopathic nephrotic syndrome that began in childhood and is frequently relapsing (FRNS) or steroid-dependent (SDNS). More information coming soon. Please visit our Patient Navigation tool for support.

RECURSOS

/

ENCUENTRA UN ESPECIALISTA

/

CONTACTO

Comercio

Mostrando 1–12 de 23 resultadosOrdenado por lo más reciente